What are the pharmacodynamics of Polymyxin B?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Polymyxin B Pharmacodynamics

Polymyxin B exerts bactericidal activity by increasing bacterial cell membrane permeability, leading to cell death, with efficacy primarily driven by the AUC/MIC ratio as the key pharmacodynamic parameter. 1

Mechanism of Action

Polymyxin B disrupts the outer membrane of gram-negative bacteria by binding to lipopolysaccharide (LPS) and phospholipids, increasing membrane permeability and causing rapid bacterial cell death 1. This mechanism is concentration-independent but time-dependent, making the area under the concentration-time curve (AUC) relative to the minimum inhibitory concentration (MIC) the critical pharmacodynamic driver.

Key Pharmacodynamic Parameters

PK/PD Index and Target Attainment

The fAUC/MIC (free drug AUC divided by MIC) is the pharmacodynamic parameter that correlates with efficacy:

  • Stasis target: fAUC/MIC of 2.1 (range 1.0-11)
  • 1-log kill: fAUC/MIC of 2.9 (range 1.0-15)
  • 2-log kill: fAUC/MIC of 4.0 (range 1.1-20) 2

However, the clinically relevant target for treatment success is an AUC/MIC ≥50, which correlates with improved clinical cure rates 3. More recent data suggests an AUCss,0-24h of 50-100 h·µg/mL optimizes efficacy while minimizing toxicity, with 76.95% of patients in this range achieving treatment success 4.

MIC Threshold and Clinical Outcomes

A polymyxin B MIC >1 mg/L is independently associated with treatment failure (adjusted OR = 0.311; 95% CI, 0.119-0.809) 3. The probability of target attainment (PTA) drops dramatically from 90.2% when MIC ≤1 mg/L to only 13.5% when MIC >1 mg/L 3. This threshold should guide clinical decision-making regarding alternative or combination therapy.

Site-Specific Pharmacodynamic Considerations

Critical Limitation in Pulmonary Infections

Polymyxin B demonstrates poor lung penetration with an epithelial lining fluid (ELF)/plasma ratio of only 15.69%, raising questions about its efficacy as monotherapy for pneumonia 4. In murine lung infection models, 2-log bacterial kill was achieved in only 2 of 8 Acinetobacter baumannii strains, and there was insufficient killing at tolerated exposures to determine reliable PD targets 2. This contrasts sharply with the thigh infection model where all strains achieved target kill rates.

Infection Site-Specific Outcomes

Clinical outcomes vary significantly by infection site 5:

  • Intra-abdominal infections (IAI): 19.7% 14-day mortality; AUC >50 mg·h/L associated with lower mortality
  • Bloodstream infections (BSI): 30.3% 14-day mortality
  • Lower respiratory tract infections (LRTI): 32.3% 14-day mortality; highest 28-day mortality at 41.4%

For IAI specifically, an AUC cutoff of 76 mg·h/L was identified as an independent predictor of 14-day mortality 5, suggesting higher exposures may be needed for deep-seated infections.

Protein Binding and Free Drug Considerations

Polymyxin B exhibits high protein binding at approximately 85.5% 4, though the FDA label notes it loses 50% of activity in the presence of serum 1. This high protein binding significantly impacts free drug concentrations available for bacterial killing. Standard dosing regimens fail to achieve adequate PTAs at the USCAST clinical breakpoint when 90% protein binding is considered 2.

Resistance Development and Combination Therapy

Monotherapy with polymyxin B for severe infections is questionable based on pharmacodynamic data 2. For carbapenem-resistant Pseudomonas aeruginosa (CRPA), guidelines suggest using two in vitro active drugs when treating severe infections with polymyxins, though specific combination recommendations cannot be made due to limited evidence 6. One retrospective study showed colistin combined with another active antibiotic had lower mortality (adjusted OR 6.63) compared to colistin alone or with inactive antibiotics for XDR-P. aeruginosa pneumonia 6.

Inflammatory Biomarkers and PD Response

TNF-α and the IL-6/IL-10 ratio correlate significantly with polymyxin B pharmacokinetic parameters, suggesting that modulation of inflammatory responses may be pivotal in treatment success beyond direct bacterial killing 4. This indicates polymyxin B's efficacy may involve immunomodulatory mechanisms, particularly in critically ill patients.

Clinical Implications

The pharmacodynamic data reveal several critical pitfalls:

  1. Standard dosing achieves inadequate exposures for MICs at current clinical breakpoints, particularly when high protein binding is considered 2
  2. Pulmonary infections represent a therapeutic challenge due to poor lung penetration, questioning monotherapy efficacy 2, 4
  3. MIC >1 mg/L should trigger consideration of alternative or combination therapy given the dramatic drop in target attainment 3
  4. Site-specific dosing may be necessary, with higher exposures potentially needed for IAI (AUC >76 mg·h/L) compared to other infection sites 5

References

Related Questions

What are the pharmacokinetic properties of Polymyxin B, including its route of administration, distribution volume, protein binding, metabolism, clearance, half‑life, and dosing adjustments in renal impairment?
What is the recommended dosing of intravenous Polymyxin B based on estimated creatinine clearance in an adult with acute kidney injury?
What is the recommended dosing regimen of Polytrim (polymyxin B 0.1 mg/mL + trimethoprim 1 mg/mL) for a 17‑year‑old female?
Can a 60-year-old female patient taking Orserdu (elacestrant) also be prescribed doxycycline and polymyxin B ophthalmic drops?
What is the appropriate polymyxin B dose in international units for a 70‑kg adult with a creatinine clearance of 20–30 mL/min, including loading and maintenance dosing?
What dopamine infusion dose should be used for renal protection, β‑1 inotropic support, and combined α/β vasoconstriction?
What is the most appropriate emollient for dry skin in the groin region?
What is the mechanism of action of Polymyxin B?
What are the pharmacokinetic properties of Polymyxin B, including its route of administration, distribution volume, protein binding, metabolism, clearance, half‑life, and dosing adjustments in renal impairment?
What antibiotics are appropriate for treating a urinary tract infection and acute gastroenteritis in a patient with chronic kidney disease who is allergic to moxifloxacin and cannot receive ceftriaxone?
In urinary tract infection, what does the complete blood count with differential look like?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.